#### ENDO PHARMA LLC

Form 4 July 22, 2005

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person \*

**ENDO PHARMA LLC** 

(Zip)

(First) (Middle)

320 PARK AVENUE

(Street)

2. Issuer Name and Ticker or Trading

Symbol

**ENDO PHARMACEUTICALS** HOLDINGS INC [ENDP]

3. Date of Earliest Transaction (Month/Day/Year)

07/22/2005

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

Estimated average

burden hours per

\_X\_\_ 10% Owner Director Officer (give title \_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

### NEW YORK, NY 10022

(State)

(City)	(State) (.	Table Table	e I - Non-Do	-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
Common Stock, par value \$.01 per share	07/22/2005		X	2,828	D	\$3	63,337,912	D			
Common Stock, par value \$.01 per share	07/22/2005		X	1,823	D	\$ 2.42	63,336,089	D			
Common Stock, par value \$.01 per share	07/22/2005		X	7,580	D	\$ 3	63,328,509	D			

### Edgar Filing: ENDO PHARMA LLC - Form 4

Common Stock, par value \$.01 per share	07/22/2005	X	777	D	\$ 2.42	63,327,732	D
Common Stock, par value \$.01 per share	07/22/2005	X	1,009	D	\$ 3	63,326,723	D
Common Stock, par value \$.01 per share	07/22/2005	X	439	D	\$ 2.42	63,326,284	D
Common Stock, par value \$.01 per share	07/22/2005	X	3,000	D	\$ 2.42	63,323,284	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)			of Derivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Option (obligation to sell)	\$ 3	07/22/2005		X		2,828	04/29/2005	08/26/2007	Common Stock	2,828
Call Option (obligation to sell)	\$ 2.42	07/22/2005		X		1,823	04/29/2005	08/26/2007	Common Stock	1,823
Call Option (obligation to sell)	\$ 3	07/22/2005		X		7,580	03/28/2005	08/26/2007	Common Stock	7,580

(9-02)

#### Edgar Filing: ENDO PHARMA LLC - Form 4

Call Option (obligation to sell)	\$ 2.42	07/22/2005	X	777	03/28/2005	08/26/2007	Common Stock	777
Call Option (obligation to sell)	\$ 3	07/22/2005	X	1,009	03/28/2005	08/26/2007	Common Stock	1,009
Call Option (obligation to sell)	\$ 2.42	07/22/2005	X	439	03/28/2005	08/26/2007	Common Stock	439
Call Option (obligation to sell)	\$ 2.42	07/22/2005	X	3,000	11/29/2004	08/26/2007	Common Stock	3,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
1 8	Director	10% Owner	Officer	Other				
ENDO PHARMA LLC 320 PARK AVENUE		X						
NEW YORK, NY 10022								

## **Signatures**

/s/ Jeffrey R. Black Chief Financial
Officer
07/22/2005

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3